MARKET OUTLOOK
The hepatocellular carcinoma (HCC) market in China is poised to experience substantial market growth. Availability of systemic targeted drugs is limited, with only three agents beyond surgery or chemotherapy available. However, the pipeline of emerging therapies is promising, with a large number of treatments being developed both within and outside China. We anticipate a significant growth in the HCC market of China over the next ten years, driven particularly by the launch and uptake of immune checkpoint inhibitors—Tecentriq, Opdivo, and Keytruda. Additionally, following the recent reforms in China’s regulatory and reimbursement landscape, manufacturers—both domestic and multinational—will be increasingly incentivized to enter the growing HCC market over the coming years.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Release date
March 2019
Geographies
China
Primary Research
Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading medical oncologists Supported by survey data collected for this and other DRG research epidemiology Diagnosed incidence of HCC by disease stage. Clinically and market relevant drug-treatable populations.
FORECAST
10-year, annualized, drug-level sales and patient shares of key HCC regimens through 2028, based on primary and secondary market research to formulate bottom-up assumptions
EMERGING THERAPIES
Phase III: 15+ drugs. Phase II: 10+ drugs. Coverage of select early-phase products.